World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
35749
World Ranking
8603
National Ranking
4433

Overview

Stephen D. Nimer is affiliated with the University of Miami in the United States. Their research primarily focuses on medicine, with a substantial number of publications in biochemistry, genetics, and molecular biology. Within these fields, their work concentrates on molecular biology, hematology, immunology, genetics, and cancer research.

The main topics covered by their research include acute myeloid leukemia, epigenetics and DNA methylation, myeloproliferative neoplasms diagnosis and treatment, cancer-related gene regulation, cancer genomics and diagnostics, histone deacetylase inhibitors, and multiple myeloma research and treatments.

Several notable papers published by Stephen D. Nimer illustrate the scope and focus of their research:

  • HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia, 2021, Nature Communications
  • RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells, 2021, Oncogene
  • Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells, 2020, Cell Reports
  • SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS, 2020, Blood
  • Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures, 2023, Blood

The venues where Stephen D. Nimer has frequently published include Blood, bioRxiv (Cold Spring Harbor Laboratory), Cell Reports, Nature Communications, and Leukemia. Blood stands out as the venue with the highest number of publications.

  • Blood
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cell Reports
  • Nature Communications
  • Leukemia

Frequent collaborators in their research efforts include Justin Taylor, Mikkael A. Sekeres, Daniel Bilbao, Jun Sun, and Na Man. These coauthors have contributed to multiple projects alongside Stephen D. Nimer, reflecting sustained research partnerships.

  • Justin Taylor
  • Mikkael A. Sekeres
  • Daniel Bilbao
  • Jun Sun
  • Na Man

Best Publications

  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

    Hagop Kantarjian;Jean-Pierre J. Issa;Craig S. Rosenfeld M.D.;John M. Bennett

  • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab

  • Report of an international working group to standardize response criteria for myelodysplastic syndromes

    B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto

  • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

    Richard M. Stone;Daniel J. DeAngelo;Virginia Klimek;Ilene Galinsky

  • ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

    Omar Abdel-Wahab;Mazhar Adli;Lindsay M. LaFave;Jie Gao

  • Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

    Thomas Fischer;Richard M. Stone;Daniel J. DeAngelo;Ilene Galinsky

  • p53 Regulates Hematopoietic Stem Cell Quiescence

    Yan Liu;Shannon E. Elf;Yasuhiko Miyata;Goro Sashida

  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

    Craig H. Moskowitz;Stephen D. Nimer;Andrew D. Zelenetz;Tania Trippett

  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

    Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock

  • Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

    Craig H. Moskowitz;Joseph R. Bertino;Jill R. Glassman;Eric E. Hedrick

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

  • Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

    Priya Koppikar;Neha Bhagwat;Outi Kilpivaara;Taghi Manshouri

  • Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

    David H. Chang;Nancy Liu;Nancy Liu;Virginia Klimek;Virginia Klimek;Hani Hassoun;Hani Hassoun

  • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes

    Greenberg Pl;Attar E;Bennett Jm;Bloomfield Cd

  • Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

    Paul A. Hamlin;Andrew D. Zelenetz;Tarun Kewalramani;Jing Qin

  • Transforming growth factor β-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation

    Joseph M. Scandura;Piernicola Boccuni;Joan Massagué;Joan Massagué;Stephen D. Nimer

  • Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

    Florian Heidel;Fian K. Solem;Frank Breitenbuecher;Daniel B. Lipka

  • JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

    Fan Liu;Xinyang Zhao;Fabiana Perna;Lan Wang

  • Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

    Neha Bhagwat;Priya Koppikar;Outi Kilpivaara;Taghi Manshouri

Frequent Co-Authors

Craig H. Moskowitz
Craig H. Moskowitz University of Miami
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Julie Teruya-Feldstein
Julie Teruya-Feldstein Icahn School of Medicine at Mount Sinai
Madhav V. Dhodapkar
Madhav V. Dhodapkar Emory University
Suresh C. Jhanwar
Suresh C. Jhanwar Memorial Sloan Kettering Cancer Center
Ross L. Levine
Ross L. Levine Memorial Sloan Kettering Cancer Center
Gary J. Schiller
Gary J. Schiller University of California, Los Angeles
Joachim Yahalom
Joachim Yahalom Memorial Sloan Kettering Cancer Center
Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Judith C. Gasson
Judith C. Gasson University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to diverse online degrees and career pathways, especially in the growing field of nursing. Many students now choose flexible, online options to advance their education and careers while balancing work or family commitments.

If you're aiming to become a Registered Nurse quickly and affordably, cheapest online accelerated BSN programs provide a fast-track route to enter the nursing workforce. For registered nurses looking to expand their qualification and earning potential, the cheapest RN to BSN programs enable you to earn your Bachelor of Science in Nursing fully online at a lower cost.

Non-nurses with a bachelor’s degree in another field can consider direct entry MSN programs online, which offer a seamless transition into advanced nursing careers. For those seeking leadership, education, or research roles, online nursing PhD programs deliver rigorous training at the doctoral level with the flexibility of distance learning.

Each pathway offers unique opportunities—whether entering healthcare for the first time or advancing to higher-level positions—making it easier than ever to chart your own course in medicine and nursing.

Best Scientists Citing Stephen D. Nimer

Trending Scientists

Recently Published Articles